177 related articles for article (PubMed ID: 35628605)
21. Novel PCSK9 (Proprotein Convertase Subtilisin Kexin Type 9) Variants in Patients With Familial Hypercholesterolemia From Cape Town.
Huijgen R; Blom DJ; Hartgers ML; Chemello K; Benito-Vicente A; Uribe KB; Behardien Z; Blackhurst DM; Brice BC; Defesche JC; de Jong AG; Jooste RJ; Solomon GAE; Wolmarans KH; Hovingh GK; Martin C; Lambert G; Marais AD
Arterioscler Thromb Vasc Biol; 2021 Feb; 41(2):934-943. PubMed ID: 33147992
[TBL] [Abstract][Full Text] [Related]
22. Apolipoprotein E gene mutations in subjects with mixed hyperlipidemia and a clinical diagnosis of familial combined hyperlipidemia.
Solanas-Barca M; de Castro-Orós I; Mateo-Gallego R; Cofán M; Plana N; Puzo J; Burillo E; Martín-Fuentes P; Ros E; Masana L; Pocoví M; Civeira F; Cenarro A
Atherosclerosis; 2012 Jun; 222(2):449-55. PubMed ID: 22481068
[TBL] [Abstract][Full Text] [Related]
23. Refinement of pathogenicity classification of variants associated with familial hypercholesterolemia: Implications for clinical diagnosis.
Di Costanzo A; Minicocci I; D'Erasmo L; Commodari D; Covino S; Bini S; Ghadiri A; Ceci F; Maranghi M; Catapano AL; Gazzotti M; Casula M; Montali A; Arca M
J Clin Lipidol; 2021; 15(6):822-831. PubMed ID: 34756585
[TBL] [Abstract][Full Text] [Related]
24. Reduced penetrance of autosomal dominant hypercholesterolemia in a high percentage of families: importance of genetic testing in the entire family.
Garcia-Garcia AB; Ivorra C; Martinez-Hervas S; Blesa S; Fuentes MJ; Puig O; Martín-de-Llano JJ; Carmena R; Real JT; Chaves FJ
Atherosclerosis; 2011 Oct; 218(2):423-30. PubMed ID: 21868016
[TBL] [Abstract][Full Text] [Related]
25. Homozygous familial hypercholesterolemia in Italy: Clinical and molecular features.
Bertolini S; Calandra S; Arca M; Averna M; Catapano AL; Tarugi P;
Atherosclerosis; 2020 Nov; 312():72-78. PubMed ID: 32977124
[TBL] [Abstract][Full Text] [Related]
26. Spectrum of mutations and phenotypic expression in patients with autosomal dominant hypercholesterolemia identified in Italy.
Bertolini S; Pisciotta L; Rabacchi C; Cefalù AB; Noto D; Fasano T; Signori A; Fresa R; Averna M; Calandra S
Atherosclerosis; 2013 Apr; 227(2):342-8. PubMed ID: 23375686
[TBL] [Abstract][Full Text] [Related]
27. Whole Exome/Genome Sequencing Joint Analysis of a Family with Oligogenic Familial Hypercholesterolemia.
Ghaleb Y; Elbitar S; Philippi A; El Khoury P; Azar Y; Andrianirina M; Loste A; Abou-Khalil Y; Nicolas G; Le Borgne M; Moulin P; Di-Filippo M; Charrière S; Farnier M; Yelnick C; Carreau V; Ferrières J; Lecerf JM; Derksen A; Bernard G; Gauthier MS; Coulombe B; Lütjohann D; Fin B; Boland A; Olaso R; Deleuze JF; Rabès JP; Boileau C; Abifadel M; Varret M
Metabolites; 2022 Mar; 12(3):. PubMed ID: 35323704
[TBL] [Abstract][Full Text] [Related]
28. In silico analysis of upstream variants in Brazilian patients with Familial hypercholesterolemia.
de Araújo JNG; de Oliveira VF; Borges JB; Dagli-Hernandez C; Marçal EDSR; Freitas RCC; Bastos GM; Gonçalves RM; Faludi AA; Jannes CE; Pereira ADC; Hirata RDC; Hirata MH; Luchessi AD; Silbiger VN
Gene; 2023 Jan; 849():146908. PubMed ID: 36167182
[TBL] [Abstract][Full Text] [Related]
29. Identification of a novel LDLR disease-causing variant using capture-based next-generation sequencing screening of familial hypercholesterolemia patients in Taiwan.
Hsiung YC; Lin PC; Chen CS; Tung YC; Yang WS; Chen PL; Su TC
Atherosclerosis; 2018 Oct; 277():440-447. PubMed ID: 30270083
[TBL] [Abstract][Full Text] [Related]
30. LDL-cholesterol and PCSK9 in patients with familial hypercholesterolemia: influence of PCSK9 variants under lipid-lowering therapy.
Hamasaki M; Sakane N; Hara K; Kotani K
J Clin Lab Anal; 2021 Nov; 35(11):e24056. PubMed ID: 34652028
[TBL] [Abstract][Full Text] [Related]
31. Next-generation sequencing to confirm clinical familial hypercholesterolemia.
Reeskamp LF; Tromp TR; Defesche JC; Grefhorst A; Stroes ESG; Hovingh GK; Zuurbier L
Eur J Prev Cardiol; 2021 Jul; 28(8):875-883. PubMed ID: 34298557
[TBL] [Abstract][Full Text] [Related]
32. Next generation sequencing to identify novel genetic variants causative of autosomal dominant familial hypercholesterolemia associated with increased risk of coronary heart disease.
Al-Allaf FA; Athar M; Abduljaleel Z; Taher MM; Khan W; Ba-Hammam FA; Abalkhail H; Alashwal A
Gene; 2015 Jul; 565(1):76-84. PubMed ID: 25839937
[TBL] [Abstract][Full Text] [Related]
33. Patients With
Doi T; Hori M; Harada-Shiba M; Kataoka Y; Onozuka D; Nishimura K; Nishikawa R; Tsuda K; Ogura M; Son C; Miyamoto Y; Noguchi T; Shimokawa H; Yasuda S
J Am Heart Assoc; 2021 Feb; 10(4):e018263. PubMed ID: 33533259
[TBL] [Abstract][Full Text] [Related]
34. ABCG5 and ABCG8 genetic variants in familial hypercholesterolemia.
Reeskamp LF; Volta A; Zuurbier L; Defesche JC; Hovingh GK; Grefhorst A
J Clin Lipidol; 2020; 14(2):207-217.e7. PubMed ID: 32088153
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetic and pharmacodynamic assessment of alirocumab in patients with familial hypercholesterolemia associated with proprotein convertase subtilisin/kexin type 9 gain-of-function or apolipoprotein B loss-of-function mutations.
Hopkins PN; Krempf M; Bruckert E; Donahue S; Yang F; Zhang Y; DiCioccio AT
J Clin Lipidol; 2019; 13(6):970-978. PubMed ID: 31767518
[TBL] [Abstract][Full Text] [Related]
36. Identification and characterization of new gain-of-function mutations in the PCSK9 gene responsible for autosomal dominant hypercholesterolemia.
Abifadel M; Guerin M; Benjannet S; Rabès JP; Le Goff W; Julia Z; Hamelin J; Carreau V; Varret M; Bruckert E; Tosolini L; Meilhac O; Couvert P; Bonnefont-Rousselot D; Chapman J; Carrié A; Michel JB; Prat A; Seidah NG; Boileau C
Atherosclerosis; 2012 Aug; 223(2):394-400. PubMed ID: 22683120
[TBL] [Abstract][Full Text] [Related]
37. Proprotein convertase subtilisin/kexin 9 V4I variant with LDLR mutations modifies the phenotype of familial hypercholesterolemia.
Ohta N; Hori M; Takahashi A; Ogura M; Makino H; Tamanaha T; Fujiyama H; Miyamoto Y; Harada-Shiba M
J Clin Lipidol; 2016; 10(3):547-555.e5. PubMed ID: 27206942
[TBL] [Abstract][Full Text] [Related]
38. Novel mutations of the PCSK9 gene cause variable phenotype of autosomal dominant hypercholesterolemia.
Allard D; Amsellem S; Abifadel M; Trillard M; Devillers M; Luc G; Krempf M; Reznik Y; Girardet JP; Fredenrich A; Junien C; Varret M; Boileau C; Benlian P; Rabès JP
Hum Mutat; 2005 Nov; 26(5):497. PubMed ID: 16211558
[TBL] [Abstract][Full Text] [Related]
39. Single Nucleotide Variants Associated With Polygenic Hypercholesterolemia in Families Diagnosed Clinically With Familial Hypercholesterolemia.
Lamiquiz-Moneo I; Pérez-Ruiz MR; Jarauta E; Tejedor MT; Bea AM; Mateo-Gallego R; Pérez-Calahorra S; Baila-Rueda L; Marco-Benedí V; de Castro-Orós I; Cenarro A; Civeira F
Rev Esp Cardiol (Engl Ed); 2018 May; 71(5):351-356. PubMed ID: 28919240
[TBL] [Abstract][Full Text] [Related]
40.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
